Abbott is facing increased competition from Dexcom in Europe, which received a CE mark for its G7 device in March and began a commercialization strategy that initially targeted large markets such as Germany and the U.K.
Abbott has been expanding its own launch and CEO Robert Ford told investors last month that the company “had very good success in Germany in terms of upgrading the base, and then with the benefits of Libre 3 actually seeing some conversions from competitive systems.”
